A look into Neogenomics Inc (NEO)’s deeper side

With 1.55 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.06 million shares. The 52-week range on NEO shows that it touched its highest point at $19.11 and its lowest point at $6.08 during that stretch. It currently has a 1-year price target of $10.62. Beta for the stock currently stands at 1.63.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NEO was up-trending over the past week, with a rise of 8.55%, but this was down by -4.38% over a month. Three-month performance dropped to -37.01% while six-month performance fell -44.95%. The stock lost -43.75% in the past year, while it has lost -48.36% so far this year. A look at the trailing 12-month EPS for NEO yields -0.61 with Next year EPS estimates of 0.30. For the next quarter, that number is 0.03. This implies an EPS growth rate of 38.18% for this year and 96.90% for next year.

Float and Shares Shorts:

At present, 128.36 million NEO shares are outstanding with a float of 127.09 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NEO since 8 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.12006 being high and $0.08731822 being low. For NEO, this leads to a yearly average estimate of $0.098233.